NEW YORK – Japanese electronics company NEC announced Friday that it has signed a memorandum of understanding with Biomy for a joint marketing partnership to develop artificial intelligence-based digital pathology platforms.
Biomy has developed its AI-based DeepPathFinder digital pathology platform to analyze images to classify cell and tissue types in specific regions. The platform also detects immune cells, such as lymphocytes and plasma cells, from hematoxylin and eosin-stained images and quantifies characteristics related to drug efficacy and prognosis, NEC said in a statement.
Under the partnership, the Tokyo-based companies will enhance the DeepPathFinder platform to discover new pathological biomarkers and use the data derived from digital images to support precision medicine and treatment planning for cancer patients.
The firms plan to offer the digital pathology platform, biomarker discovery services, and guidance for obtaining regulatory approval for medical devices that use the newly discovered biomarkers to pharmaceutical and biotech companies as well as for academic research.
Financial and other terms of the deal were not disclosed.